{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:55:19Z","timestamp":1757620519754,"version":"3.44.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10067-025-07598-3","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T12:05:43Z","timestamp":1753963543000},"page":"3753-3764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rituximab in the COVID-19 era: The impact of albumin and IgG on patients with immune-mediated inflammatory diseases"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8101-7113","authenticated-orcid":false,"given":"Pei-Hsinq","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4794-9438","authenticated-orcid":false,"given":"Cheng-Hsun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8618-9945","authenticated-orcid":false,"given":"Chiao-Feng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2868-7313","authenticated-orcid":false,"given":"Ting-Wei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2827-1692","authenticated-orcid":false,"given":"Ting-Yuan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8058-7566","authenticated-orcid":false,"given":"Song-Chou","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"6","key":"7598_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","volume":"130","author":"TS Athni","year":"2023","unstructured":"Athni TS, Barmettler S (2023) Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. Ann Allergy Asthma Immunol 130(6):699\u2013712","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"7598_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","volume":"36","author":"EAA Christou","year":"2017","unstructured":"Christou EAA, Giardino G, Worth A, Ladomenou F (2017) Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab. Int Rev Immunol 36(6):352\u2013359","journal-title":"Int Rev Immunol"},{"issue":"5","key":"7598_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/rheumatology\/key394","volume":"58","author":"S Wijetilleka","year":"2019","unstructured":"Wijetilleka S, Jayne DR, Mukhtyar C et al (2019) Recommendations for the management of secondary hypogammaglobulinemia due to B cell targeted therapies in autoimmune rheumatic diseases. Rheumatology (Oxford) 58(5):889\u2013896","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"7598_CR4","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","volume":"80","author":"JA Sparks","year":"2021","unstructured":"Sparks JA, Wallace ZS, Seet AM et al (2021) Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry. Ann Rheum Dis 80(9):1137\u20131146","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"7598_CR5","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1080\/09546634.2020.1800565","volume":"33","author":"A Di Altobrando","year":"2022","unstructured":"Di Altobrando A, Patrizi A, Abbenante D, Bardazzi F (2022) Rituximab: a safe therapeutic option during the COVID-19 pandemic? J Dermatolog Treat 33(2):1197","journal-title":"J Dermatolog Treat"},{"issue":"15","key":"7598_CR6","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1080\/14656566.2022.2131395","volume":"23","author":"B Bennett","year":"2022","unstructured":"Bennett B, Tahir H, Ganguly S, Moorthy A (2022) An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies. Expert Opin Pharmacother 23(15):1695\u20131700","journal-title":"Expert Opin Pharmacother"},{"key":"7598_CR7","doi-asserted-by":"crossref","unstructured":"Kawka L, Fabacher T, Sauleau E, Coury F, Arnaud L; Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie (SFR). Factors associated with severity and mortality of COVID-19 in French patients with connective tissue diseases and rheumatoid arthritis: a nation-wide, population-based analysis of the French national medico-administrative SNDS database. Joint Bone Spine, 2024: p. 105818.","DOI":"10.1016\/j.jbspin.2024.105818"},{"issue":"7","key":"7598_CR8","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","volume":"80","author":"A Strangfeld","year":"2021","unstructured":"Strangfeld A, Sch\u00e4fer M, Gianfrancesco MA et al (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 80(7):930\u2013942","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7598_CR9","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","volume":"3","author":"J Avouac","year":"2021","unstructured":"Avouac J, Drumez E, Hachulla E et al (2021) COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol 3(6):e419\u2013e426","journal-title":"Lancet Rheumatol"},{"key":"7598_CR10","doi-asserted-by":"crossref","unstructured":"Wiedermann, C.J., Hypoalbuminemia as Surrogate and Culprit of Infections. Int J Mol Sci, 2021. 22(9).","DOI":"10.3390\/ijms22094496"},{"issue":"6","key":"7598_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM199902113400607","volume":"340","author":"C Gabay","year":"1999","unstructured":"Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340(6):448\u2013454","journal-title":"N Engl J Med"},{"issue":"5","key":"7598_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nrrheum.2011.37","volume":"7","author":"B Rhodes","year":"2011","unstructured":"Rhodes B, F\u00fcrnrohr BG, Vyse TJ (2011) C-reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol 7(5):282\u2013289","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"7598_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/ncprheum0572","volume":"3","author":"E Dayer","year":"2007","unstructured":"Dayer E, Dayer JM, Roux-Lombard P (2007) Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases. Nat Clin Pract Rheumatol 3(9):512\u2013520","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"5","key":"7598_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.14740\/jocmr4507","volume":"13","author":"R Acharya","year":"2021","unstructured":"Acharya R, Poudel D, Bowers R et al (2021) Low Serum Albumin Predicts Severe Outcomes in COVID-19 Infection: A Single-Center Retrospective Case-Control Study. J Clin Med Res 13(5):258\u2013267","journal-title":"J Clin Med Res"},{"issue":"3","key":"7598_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10238-021-00686-z","volume":"21","author":"P Paliogiannis","year":"2021","unstructured":"Paliogiannis P, Mangoni AA, Cangemi M, Fois AG, Carru C, Zinellu A (2021) Serum albumin concentrations are associated with disease severity and outcomes in coronavirus 19 disease (COVID-19): a systematic review and meta-analysis. Clin Exp Med 21(3):343\u2013354","journal-title":"Clin Exp Med"},{"issue":"1","key":"7598_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13054-020-02995-3","volume":"24","author":"M Aziz","year":"2020","unstructured":"Aziz M, Fatima R, Lee-Smith W, Assaly R (2020) The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis. Crit Care 24(1):255","journal-title":"Crit Care"},{"key":"7598_CR17","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.ijbiomac.2021.10.095","volume":"193","author":"G Rabbani","year":"2021","unstructured":"Rabbani G, Ahn NS (2021) Roles of human serum albumin in prediction, diagnoses and treatment of COVID-19. Int J Biol Macromol 193:948\u2013955","journal-title":"Int J Biol Macromol"},{"issue":"7","key":"7598_CR18","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79(7):859\u2013866","journal-title":"Ann Rheum Dis"},{"issue":"6585","key":"7598_CR19","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1126\/science.abm8108","volume":"375","author":"M Merad","year":"2022","unstructured":"Merad M, Blish CA, Sallusto F, Iwasaki A (2022) The immunology and immunopathology of COVID-19. Science 375(6585):1122\u20131127","journal-title":"Science"},{"issue":"5","key":"7598_CR20","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/cid\/ciac868","volume":"76","author":"ES Ford","year":"2023","unstructured":"Ford ES, Simmons W, Karmarkar EN et al (2023) Successful treatment of prolonged, severe coronavirus disease 2019 lower respiratory tract disease in a B cell acute lymphoblastic leukemia patient with an extended course of remdesivir and nirmatrelvir\/ritonavir. Clin Infect Dis 76(5):926\u2013929","journal-title":"Clin Infect Dis"},{"key":"7598_CR21","doi-asserted-by":"crossref","unstructured":"Martinez MA, Chen TY, Choi H, et al., Extended Remdesivir Infusion for Persistent Coronavirus Disease 2019 Infection. Open Forum Infect Dis, 2022. 9(8): p. ofac382.","DOI":"10.1093\/ofid\/ofac382"},{"key":"7598_CR22","doi-asserted-by":"crossref","unstructured":"Snell LB, McGreal-Bellone A, Nye C, et al., A Multinational Case Series Describing Successful Treatment of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Caused by Omicron Sublineages With Prolonged Courses of Nirmatrelvir\/Ritonavir. Open Forum Infectious Diseases, 2024. 11(1).","DOI":"10.1093\/ofid\/ofad612"},{"issue":"11","key":"7598_CR23","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/art.40937","volume":"71","author":"MY Md Yusof","year":"2019","unstructured":"Md Yusof MY, Vital EM, McElvenny DM et al (2019Nov) Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol 71(11):1812\u20131823","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"7598_CR24","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1007\/s00277-021-04662-1","volume":"100","author":"H Levavi","year":"2021","unstructured":"Levavi H, Lancman G, Gabrilove J (2021Nov) Impact of rituximab on COVID-19 outcomes. Ann Hematol 100(11):2805\u20132812","journal-title":"Ann Hematol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07598-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07598-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07598-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:29:48Z","timestamp":1757323788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07598-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7598"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07598-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declared no potential conflicts of interest.The source(s) of support in the form of grants or industrial support: none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}